![Lawsuit: Investors Blind to Ocular Therapeutix’s Quality Issues](/media/news-ocular-therapeutix.jpg)
Lawsuit: Investors Blind to Ocular Therapeutix’s Quality Issues
July 7, 2017 Ocular Therapeutix, Inc. and four executives are facing a stockholder’s claims that they misled investors about the quality and future success of Dextenza – a drug currently undergoing clinical trials for the treatment of certain eye conditions.